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Abstract. [Yttrium-90-DOTA-Tyr3]-octreotide (DOTA-
TOC) and [177Lu-DOTA-Tyr3-Thr8]-octreotide (DOTA-
TATE) are used for peptide receptor-mediated radionu-
clide therapy (PRMRT) in neuroendocrine tumours. No
human data comparing these two compounds are avail-
able so far. We used 111In as a surrogate for 90Y and
177Lu and examined whether one of the 111In-labelled
peptides had a more favourable biodistribution in pa-
tients with neuroendocrine tumours. Special emphasis
was given to kidney uptake and tumour-to-kidney ratio
since kidney toxicity is usually the dose-limiting factor.
Five patients with metastatic neuroendocrine tumours
were injected with 222 MBq 111In-DOTATOC and 111In-
DOTATATE within 2 weeks. Up to 48 h after injection,
whole-body scans were performed and blood and urine
samples were collected. The mean absorbed dose was
calculated for tumours, kidney, liver, spleen and bone
marrow. In all cases 111In-DOTATATE showed a higher
uptake (%IA) in kidney and liver. The amount of 111In-
DOTATOC excreted into the urine was significantly
higher than for 111In-DOTATATE. The mean absorbed
dose to the red marrow was nearly identical. 111In-
DOTATOC showed a higher tumour-to-kidney absorbed
dose ratio in seven of nine evaluated tumours. The vari-
ability of the tumour-to-kidney ratio was high and the
significance level in favour of 111In-DOTATOC was
P=0.065. In five patients the pharmacokinetics of 111In-
DOTATOC and 111In-DOTATATE was found to be com-
parable. The two peptides appear to be nearly equivalent
for PRMRT in neuroendocrine tumours, with minor ad-
vantages for 111In/90Y-DOTATOC; on this basis, we shall
continue to use 90Y-DOTATOC for PRMRT in patients
with metastatic neuroendocrine tumours.
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Introduction
Somatostatin receptors have been identified in high den-
sity on neuroendocrine tumours as well as on tumours of
the central nervous system, the breast, the lung and the
lymphatic tissue [1]. To demonstrate the presence of so-
matostatin receptors in vivo, scintigraphy with radiola-
belled somatostatin analogues such as [111In-DTPA-D-
Phe1]-octreotide (Octreoscan) has become the gold stan-
dard [2]. Peptide receptor-mediated radionuclide therapy
(PRMRT) has been used for several years in the treat-
ment of progressive, metastasised, somatostatin receptor-
positive tumours. Both somatostatin analogues, [90Y-
DOTA-Tyr3]-octreotide (DOTATOC) and [177Lu-DOTA-
Tyr3-Thr8]-octreotide (DOTATATE), have been used for
this purpose and have shown encouraging results [3–6].
Recently, Kwekkeboom et al. showed that 177Lu-
DOTATATE had an up to fourfold higher tumour uptake
than [111In-DTPA]-octreotide in six patients [7]. More-
over, Reubi et al. have shown that Y(III)-DOTATATE has
an approximately sevenfold higher binding affinity to the
somatostatin receptor subtype 2 (hsst2) compared with
Y(III)-DOTATOC [8], which suggests that 111In/90Y-
DOTATATE would show a higher tumour uptake in pa-
tients. However, no patient data comparing these two
compounds are available so far.
Therefore, the aim of this study was to compare 
the pharmacokinetics of 111In-DOTATOC and 111In-
DOTATATE in the same patients. Special emphasis was
placed on the mean absorbed doses for tumour, kidney
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and bone marrow since the dose-limiting organs for
PRMRT with radiolabelled somatostatin analogues are
usually the kidneys and the bone marrow [3, 4, 9]. In 
addition, 111In-DOTATOC/111In-DOTATATE was taken
as a surrogate for 90Y-DOTATOC/90Y-DOTATATE and
the calculated mean absorbed doses of 90Y-DOTATOC
were compared with the doses of this radiopeptide
known from the literature [10–13].
Materials and methods
Patients. Five male patients (age 49–73, mean 62 years) (Table 1)
with known metastatic neuroendocrine tumours were injected with
222 MBq 111In-DOTATOC and 222 MBq 111In-DOTATATE, with
an interval of 2 weeks between the administrations. In three 
patients, 111In-DOTATATE was injected first, while in two, 111In-
DOTATOC was injected first. In two patients the primary tumour
was in the pancreas. In three patients the origin of the disease was
unknown. None of the patients had received medication with so-
matostatin analogues (Octreotide s/c or LAR, Novartis Pharma;
Lanreotide, Ipsen Ltd.) within the 8 weeks before the examina-
tions. All patients had a histologically confirmed neuroendocrine
tumour and had been treated with 90Y-DOTATOC before. There
were at least 14 months between the last therapy and the beginning
of the study (14–25 months, mean 20.25 months). Metastatic dis-
ease had been confirmed in all cases by recent morphological im-
aging with magnetic resonance imaging (MRI), computed tomo-
graphy (CT) or ultrasonography. Based on these examinations, the
tumour volumes were calculated. The study was approved by the
Swiss authorities and by the local ethical committee (Ethikkom-
mission beider Basel). All patients gave informed consent.
Radiopharmaceuticals. Both somatostatin analogues, DOTATOC
and DOTATATE, were synthesised in house according to a previ-
ously published procedure [8, 14] and radiolabelled with 111In as
published previously [15]. 111In was purchased from Tyco Health-
care (Petten, The Netherlands). The labelling yield and the radio-
pharmaceutical purity were checked using C18 reversed-phase
high-performance liquid chromatography.
Imaging. All images were acquired with a dual-head gamma cam-
era Picker Prism 2000 XP (Philips, Eindhoven, The Netherlands).
The windows were centred over both 111In photon peaks (245 
and 172 keV) with a width of 20%. Parallel-hole, medium-energy
general-purpose collimators were used. For both compounds, the
same protocol was followed: dynamic imaging up to 20 min post
injection with a field of view over the kidneys and liver from the
posterior projection (80 images, 15 s per image). Whole-body
scans were obtained 1, 2, 4, 24 and 48 h after injection. The acqui-
sition time for all whole-body scans was 15 min.
Measurement of radioactivity in blood and urine. Blood samples
were drawn 10, 20, 30 and 60 min and 2, 4, 24 and 48 h after in-
jection. Urine was collected in four intervals: 0–2, 2–4, 4–24 and
24–48 h after injection. Radioactivity in blood and urine was mea-
sured with a gamma counter (Cobra II Autogamma, Packard, A
Canberra Company).
Pharmacokinetics and dosimetry. Regions of interest (ROIs) were
drawn manually on the whole-body scans from the anterior and
posterior projections for the whole body, the kidneys, the spleen,
the liver, the bladder and tumour lesions. The Odyssey XP pro-
gram was used. Background regions were placed close to the ROIs
for background correction. Parts of the organs showing tumour in-
filtration or superimposition were excluded from the evaluation of
organ uptake. The geometric mean value, between anterior and
posterior, was taken and corrected for attenuation and physical de-
cay. Whole-body activity acquired 1 h after injection was defined
as 100% of the injected activity (IA). The patients did not empty
the bladder during this period. All data for the whole body, organs
and tumour lesions were expressed in %IA. A compartment model
as described previously was used to calculate the residence time
from the time-activity data resulting from the scans [10]. The 
activity in blood was fitted by three exponential curves. The resi-
dence times were determined using these data and the respective
half-lives of 111In and 90Y. Assuming no specific uptake in the red
marrow, a uniform distribution of the activity, and that the red
marrow clearance was the same as in blood, the dose to the red
marrow was calculated with a correction factor of 1 from the resi-
dence time in blood as published previously [10].
Statistics. Paired t test was used to determine statistical signifi-
cance. Differences at the 95% confidence level (P<0.05) were
considered significant.
Results
Patients showed no clinical adverse reactions and no
side-effects after the intravenous injection of 111In-
DOTATOC or 111In-DOTATATE.
Pharmacokinetic studies
Figure 1 displays the mean plasma radioactivity (and
standard deviation) expressed as %IA. The clearance of
both peptides was fast. The time-activity in blood could
be fitted by three exponential curves. In all patients and
for both radiopeptides, the activity in blood decreased to
less than 10% within the first 4 h. 111In-DOTATOC
showed a somewhat slower clearance initially. After 24
and 48 h, a slightly higher amount of 111In-DOTATATE
was found in the blood of all patients. The mean resi-
dence time (τ) was 1.178 h (SD±0.19 h) for 111In-DOTA-
TOC and 1.156 h (SD±0.32 h) for 111In-DOTATATE.
Therefore, the mean absorbed dose to the red marrow
was not significantly different between the two com-
pounds (Table 2). Only a small interpatient variability
was found (Table 3).
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Table 1. Patient details
Patient Age (yrs) Histology and primary tumour
1 69 Neuroendocrine tumour of the pancreas
2 65 Neuroendocrine tumour of unknown origin
3 73 Neuroendocrine tumour of unknown origin
4 53 Neuroendocrine tumour of unknown origin
5 49 Neuroendocrine tumour of the pancreas
Cumulative activity excreted into the urine was high-
er for 111In-DOTATOC in all samples and all patients
(Fig. 2). For all periods (0–2, 2–4, 4–24 and 24–48 h) the
difference was significant (P<0.05).
Biodistribution and dosimetry
The distribution pattern of 111In-DOTATATE was initially
comparable to the pattern using 111In-DOTATOC. In four
of the five patients a distinct specific uptake in tumour
sites was seen after approximately 2 min. Also, there was
fast visualisation of the liver, kidneys and spleen. The fifth
patient showed no tumour uptake with either compound
due to an impressive decrease in tumour load after 90Y-
DOTATOC therapy. In this patient, only two small liver
metastases <1 cm were found on a recent CT scan.
We found higher mean absorbed doses to the kidneys
and liver for 111In-DOTATATE. The calculated difference
for 90Y, when taking 111In as a surrogate, was significant
in the liver (P<0.05) but not in the kidneys (P=0.135).
The dose to the spleen showed a high interpatient vari-
ability. Although in three patients the mean absorbed
dose to the spleen for 111In-DOTATATE was higher 
(Table 2), the difference did not reach significance
(P=0.205). The calculated absorbed doses for 90Y-
DOTATOC (taking 111In-DOTATOC as the surrogate) for
the various organs are comparable with the doses known
from the literature [10–12]. Our values, along with liter-
ature data, are shown in Table 3.
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Table 2. Mean absorbed doses (mGy/MBq) for 90Y-DOTATOC (TOC) and 90Y-DOTATATE (TATE) derived from biodistribution data in
five patients using the 111In-labelled peptides
Patient Kidneys Liver Spleen Red Marrow
TOC TATE TOC TATE TOC TATE TOC TATE
1 2.95 3.53 0.88 1.31 15.5 13.4 0.15 0.15
2 3.15 3.62 0.82 2.39 1.71 3.3 0.17 0.16
3 3.60 3.62 1.33 2.16 4.8 7.74 0.17 0.20
4 2.59 3.58 1.15 1.34 4.71 7.98 0.19 0.16
5 1.91 5.17 0.41 1.18 6.12 18.5 0.15 0.13
Mean ± SD 2.84±0.64 3.90±0.71 0.92±0.35 1.68±0.56 6.57±5.25 10.18±5.87 0.17±0.02 0.16±0.03
P value 0.135 0.031 0.205 0.591
Table 3. Comparison of mean absorbed doses (±SD) (mGy/MBq) for 90Y-DOTATOC derived from 111In-DOTATOC and 86Y-DOTATOC
Forrer et al. this study Cremonesi et al. [10] Förster et al. [11] Krenning et al. [12]
Derived from 111In-DOTATOC 111In-DOTATOC 86Y-DOTATOC 86Y-DOTATOC
Kidney 2.84 (±0.64) 3.31 (±2.22) 2.73 (±1.41) 2.1 (±0.78)
Liver 0.92 (±0.35) 0.72 (±0.57) 0.66 (±0.15) –
Spleen 6.57 (±5.25) 7.62 (±6.30) 2.32 (±1.97) 1.83 (±1.45)
Red marrow 0.17 (±0.02) 0.03 (±0.01) 0.049 (±0.002) 0.11 (±0.06)
Fig. 1. Blood clearance expressed as percentage of the injected 
activity (%IA) in the blood (mean ± SD)
Fig. 2. Cumulative activity excreted into the urine expressed as
%IA (mean ± SD)
Overall, nine metastases could be evaluated in scinti-
graphic images and correlated with a lesion on CT, MRI
or sonography. In five of the nine lesions, a somewhat
higher mean absorbed dose (mGy/MBq) was found for
111In-DOTATOC; however, high variability between the
lesions was observed (Table 4).
Since most often the dose-limiting organ in therapy
with radiopeptides is the kidneys, the absorbed dose ratio
of lesion to kidneys will determine the therapeutic win-
dow. Due to the high variability in mean absorbed doses
in the tumours, we found a high variability in the dose
ratios as well. However, in seven out of nine lesions,
111In-DOTATOC showed a higher ratio and the differ-
ence in mean values almost reached significance
(P=0.065) (Table 4).
In two patients, whole-body scans 4, 24 and 48 h after
injection showed better visualisation of liver metastases
with 111In-DOTATOC. In the other three patients, the
scans were visually identical. The better demarcation
was due to the lower uptake in the normal liver. Findings
in one of the patients with better demarcation of the liver
metastases with 111In-DOTATOC are shown in Fig. 3.
Discussion
In this study, both radiopeptides, 111In-DOTATOC and
111In-DOTATATE, showed the expected high specific up-
take in somatostatin receptor-positive tissue. Visually,
the results obtained with the two compounds were com-
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Fig. 3. Whole-body scans of
patient no. 2, 4 h after injection
of 222 MBq 111In-DOTATOC
(left) and 111In-DOTATATE
(right). Better visualisation of
the tumours in the liver can be
seen in 111In-DOTATOC
Table 4. Mean absorbed tumour doses (mGy/MBq) for 90Y-DOTATOC and 90Y-DOTATATE derived from biodistribution data in nine
tumours using the 111In-labelled peptides and the respective tumour-to-kidney ratio
Patient Lesion (localisation) Tumour doses (mGy/MBq) Tumour-to-kidney ratio
DOTATOC DOTATATE DOTATOC DOTATATE
1 1 (ln) 12.23 12.12 4.15 3.43
2 (li) 33.34 24.26 11.30 6.87
2 3 (li) 2.88 4.60 0.91 1.27
4 (li) 6.31 8.19 2.00 2.26
4 5 (b) 2.80 1.73 1.08 0.48
6 (li) 41.66 55.54 16.08 15.51
7 (li) 26.72 15.93 10.32 4.45
8 (li) 15.77 12.13 6.09 3.39
5 9 (b) 2.37 6.15 1.24 1.18
Mean ± SD 16.01±14.64 15.63±16.40 5.91±5.48 4.32±4.36
P value 0.879 0.065
(ln), Abdominal lymph node; (li), liver; (b), bone
parable, although better visualisation of some liver me-
tastases was found with 111In-DOTATOC. The dosimetric
analyses showed small differences between the radiopep-
tides, but a significantly higher mean absorbed dose to
the liver was found for 111In-DOTATATE, and a
favourable tumour-to-kidney ratio (P=0.065) was calcu-
lated for 111In-DOTATOC. These findings were unex-
pected since data from animal models have shown a
more favourable biodistribution for DOTATATE-derived
radiopeptides [16]. Because the total administered thera-
peutic dose with radiolabelled somatostatin analogues is
determined by tumour-to-kidney mean absorbed dose ra-
tios (and/or tumour-to-red marrow absorbed dose ratios),
these ratios are the most important parameters for thera-
peutic success. Slightly better results were found for
111In-DOTATOC in three of the four patients with well-
defined uptake in metastases.
In this study, we used 111In as a surrogate for 90Y, as
we assume high similarity between the tracers although
differences in pharmacological parameters have been
shown if DOTATOC is labelled with 67Ga/68Ga instead
of 111In [15]. In addition, de Jong et al. [17] showed dif-
ferences in the biodistribution of 111In-DOTATOC and
90Y-DOTATOC in rats bearing the CA 20948 tumour. 
On the other hand, Froidevaux et al. [18] showed an 
essentially similar performance of 111In-DOTATOC and
90Y-DOTATOC when using the AR4-2J bearing mouse
model.
The mean absorbed doses calculated for 90Y-DOTA-
TOC are comparable with the absorbed doses published
in the literature so far [9–13] (Table 3), confirming the
accuracy of our methodology. Although the absorbed
doses calculated for the red marrow were higher than the
doses reported by Cremonesi et al. [10] and Förster et al.
[11], they are comparable with the doses published by
Krenning et al. [12] (Table 3).
A high interpatient absorbed tumour dose variability
was found, which is not unexpected as receptor densities
vary markedly among patients and tumours. This fact is
well known from the literature [10–13].
A better tumour-to-kidney absorbed dose ratio can be
achieved by co-infusion of amino acids, especially lysine
and arginine [13, 19–21]. It is unclear whether the results
obtained in comparing 111In-DOTATOC and 111In-
DOTATATE would be the same if the measurements
were to be performed with co-infusion of amino acids.
The difference in charge (positive overall charge of 111In-
DOTATOC and neutral charge of 111In-DOTATATE)
might lead to different results with regard to the kidney
absorbed dose after amino acid co-infusion.
The accuracy of the absolute values obtained by 
organ dosimetry using gamma-scintigraphy may still be
limited owing to many potential sources of error. How-
ever, since the main aim of this study was to compare
two compounds in the same patients with the same meth-
ods, this would not have affected the reliability of the
findings.
We could not confirm the assumption, based on ani-
mal experiments, that 90Y-DOTATATE may have more
favourable characteristics for PRMRT compared with
90Y-DOTATOC. Therefore, we will continue treatment
with 90Y-DOTATOC.
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